Keyword search

Filter results by

Search Help
Currently selected filters that can be removed

Keyword(s)

Type

1 facets displayed. 0 facets selected.

Year of publication

1 facets displayed. 1 facets selected.

Survey or statistical program

1 facets displayed. 1 facets selected.
Sort Help
entries

Results

All (2)

All (2) ((2 results))

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25

  • Articles and reports: 88F0006X2001011
    Description:

    This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.

    Release date: 2001-08-28
Data (0)

Data (0) (0 results)

No content available at this time.

Analysis (2)

Analysis (2) ((2 results))

  • Articles and reports: 88F0006X2001012
    Description:

    As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.

    Release date: 2001-09-25

  • Articles and reports: 88F0006X2001011
    Description:

    This paper provides a summary of the strategies and business practices of biotechnology firms, and information on the business environment faced by these firms. These issues, considered in conjunction with information on revenue, research and development, import and export, product pipeline and human resources characteristics of biotechnology firms, contribute to a more comprehensive portrait of the biotechnology sector in Canada.

    Release date: 2001-08-28
Reference (0)

Reference (0) (0 results)

No content available at this time.

Date modified: